Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

14.20 +0.14 (+1.00%)
Streaming Delayed Price Updated: 2:46 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks ↗
Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗
One is speculative, the other is a reliable blue chip company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
From Amarin Corporation plc
Via GlobeNewswire
Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 ↗
Via Chartmill
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Amarin Corp ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Amarin (AMRN) Q4 2025 Earnings Call Transcript ↗
Amarin (AMRN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International Markets 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Corp (NASDAQ:AMRN) Beats Q3 2025 Earnings and Revenue Estimates ↗
Amarin (AMRN) Q3 2025 earnings beat expectations with strong revenue growth and a narrowed loss, driven by its new global partner strategy. 
Via Chartmill
Topics Earnings
News headline image
Amarin Reports Third Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Second Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA ↗
Amarin Corporation (NASDAQ: AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its... 
Via Benzinga
News headline image
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges ↗
Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to improve cash flow 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Tuesday? ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.